Equities

Kainos Laboratories Inc

4556:TYO

Kainos Laboratories Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,136.00
  • Today's Change-3.00 / -0.26%
  • Shares traded1.90k
  • 1 Year change+12.59%
  • Beta0.8782
Data delayed at least 20 minutes, as of May 31 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

  • Revenue in JPY (TTM)5.06bn
  • Net income in JPY637.97m
  • Incorporated1975
  • Employees144.00
  • Location
    Kainos Laboratories Inc2-38-18, HongoBUNKYO-KU 113-0033JapanJPN
  • Phone+81 338164123
  • Fax+81 338166550
  • Websitehttp://www.kainos.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Human Metabolome Technologies Inc1.34bn285.75m3.80bn57.0013.291.9710.272.8448.3148.31226.62326.170.564317.823.8023,500,000.0012.04--15.43--63.89--21.33--3.84124.760.1061--6.21--6.71------
Kubota Pharmaceutical Holdings Co Ltd39.74m-1.39bn3.83bn12.00--1.64--96.32-24.82-24.820.71141.580.01180.381526.893,312,000.00-41.32-36.51-45.53-39.4772.88---3,492.38-13,528.878.97--0.0555--383.24--26.11--24.38--
FunPep Co Ltd676.00k-760.40m4.03bn15.00--1.71--5,963.56-31.52-31.520.02890.560.0002--3.3945,066.67-26.86-27.10-28.42-28.75-----112,484.90-815.8217.27-1,006.150.00---50.33-72.8020.39---13.14--
BrightPath Biotherapeutics Co Ltd72.00k-1.17bn4.11bn32.00--4.19--57,147.16-18.30-18.300.001113.840.00005--2.36---79.69-51.56-87.69-54.3275.0068.63-1,622,336.00-22,321.82---435.390.1031---98.64-78.4721.37---46.55--
Perseus Proteomics Inc100.40m-1.10bn4.24bn24.00--2.77--42.25-93.74-93.748.52117.150.04713.358.55---51.85-41.34-54.94-43.4387.3391.72-1,100.04-891.2612.77------6.58-18.31-40.34--60.30--
Delta-Fly Pharma Inc0.00-1.43bn4.33bn11.00--3.51-----197.24-197.240.00149.780.00-------120.07-67.70-141.25-72.02-----------243.15---------7.57---9.04--
Kringle Pharma Inc77.93m-904.81m4.58bn13.00--1.89--58.82-159.92-159.9213.58356.640.027--2.805,994,308.00-31.29-19.00-33.20-20.23-----1,161.12-156.5112.85--0.00---82.33---157.41------
Immuno-Biological Laboratories Co., Ltd.816.70m186.69m4.68bn60.0025.043.70--5.7320.0520.0587.69135.860.5350.93584.53--12.23-13.9714.68-16.3963.3457.7322.86-39.233.65--0.1572--2.780.8924164.44------
Renascience Inc194.17m-258.34m4.68bn3.00--2.91--24.09-20.32-20.3215.27126.400.089-------11.84---12.49--85.31---133.05------0.1814--93.11--23.07------
Kidswell Bio Corp2.43bn-1.42bn4.92bn41.00--5.85--2.03-40.81-40.8168.7921.350.54151.842.47---31.67-57.41-51.25-81.1342.7555.20-58.49-123.521.70-28.910.7559---12.4318.93-116.31------
KAINOS Laboratories, Inc.5.06bn637.97m5.18bn144.007.450.76436.841.02152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
OncoTherapy Science, Inc.610.12m-1.29bn5.27bn60.00--13.54--8.63-6.09-6.092.871.620.5139.087.69---108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Solasia Pharma KK408.00m-1.18bn5.42bn24.00--2.80--13.28-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
Noile-Immune Biotech Inc311.30m-975.80m5.67bn28.00--1.06--18.22-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
Cyfuse Biomedical KK64.79m-645.40m6.05bn21.00--1.97--93.37-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
DNA Chip Research Inc490.46m-248.29m6.17bn36.00--8.42--12.58-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
Data as of May 31 2024. Currency figures normalised to Kainos Laboratories Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.84%Per cent of shares held by top holders
HolderShares% Held
Lemanik Invest SAas of 30 Apr 202438.00k0.83%
Simplex Asset Management Co., Ltd.as of 09 May 2024200.000.00%
Data from 30 Apr 2024 - 23 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.